149 related articles for article (PubMed ID: 26642762)
1. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers.
Pendharkar N; Gajbhiye A; Taunk K; RoyChoudhury S; Dhali S; Seal S; Mane A; Abhang S; Santra MK; Chaudhury K; Rapole S
J Proteomics; 2016 Jan; 132():112-30. PubMed ID: 26642762
[TBL] [Abstract][Full Text] [Related]
2. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics.
Gajbhiye A; Dabhi R; Taunk K; Vannuruswamy G; RoyChoudhury S; Adhav R; Seal S; Mane A; Bayatigeri S; Santra MK; Chaudhury K; Rapole S
Proteomics; 2016 Sep; 16(17):2403-18. PubMed ID: 27324523
[TBL] [Abstract][Full Text] [Related]
3. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
6. MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes.
Blaschke E; Abe H
J Magn Reson Imaging; 2015 Oct; 42(4):920-4. PubMed ID: 25758675
[TBL] [Abstract][Full Text] [Related]
7. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
8. Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer.
Raphael J; Gong IY; Nofech-Mozes S; Bartlett J; Nafisi H; Verma S
J Clin Pathol; 2016 Jun; 69(6):552-5. PubMed ID: 26951081
[No Abstract] [Full Text] [Related]
9. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
10. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
11. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
12. Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer.
Grant KA; Pienaar FM; Brundyn K; Swart G; Gericke GS; Myburgh EJ; Wright CA; Apffelstaedt JP; Kotze MJ
Breast; 2015 Apr; 24(2):137-42. PubMed ID: 25586984
[TBL] [Abstract][Full Text] [Related]
13. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
14. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
Bae MS; Seo M; Kim KG; Park IA; Moon WK
Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman S; Basak T; Gupta P; Mishra S; Kumar V; Sengupta S; Shukla Y
J Proteomics; 2016 Oct; 148():183-93. PubMed ID: 27498393
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
[TBL] [Abstract][Full Text] [Related]
17. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.
Korwar AM; Bhonsle HS; Ghole VS; Gawai KR; Koppikar CB; Kulkarni MJ
OMICS; 2013 Jan; 17(1):27-40. PubMed ID: 23301641
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical profile and clinical-pathological variables in breast cancer.
Cintra JR; Teixeira MT; Diniz RW; Gonçalves Junior H; Florentino TM; Freitas GF; Oliveira LR; Neves MT; Pereira T; Guerra MR
Rev Assoc Med Bras (1992); 2012; 58(2):178-87. PubMed ID: 22569612
[TBL] [Abstract][Full Text] [Related]
20. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
